Anthera Pharmaceuticals, Inc. announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”). The interim futility analysis was conducted by RESULT’s Data Monitoring Committee which is comprised of experts appointed by the Cystic Fibrosis Foundation’s Therapeutics Development Network. Anthera completed patient recruitment in the RESULT study in November 2017, and based on the interim futility analysis, the study will proceed, as planned, with topline data expected in first quarter of 2018. The RESULT study allows for more frequent and higher dose adjustments based upon clinical signs and symptoms than the previous Phase 3 SOLUTION study. As with current practice with porcine pancreatic enzyme replacement therapies (“PERTs”), the RESULT study allows for dose titrations of Sollpura on an individualized basis to achieve maximum therapeutic benefit. Sollpura has the potential to become the first non-porcine PERT, which may provide a reduction in the size and number of pills patients must consume daily due to the significantly more compact formulation of Sollpura than porcine PERTs.